DUBLIN–(BUSINESS WIRE)–Research Report on China’s Nicorandil Market, 2022-2031 has been added to from ResearchAndMarkets.com offer.
Analyst survey data shows that from 2017 to 2021, the sales value of nicorandil in the Chinese market has steadily increased year by year. Even in the face of COVID-19, the sales value increased further in 2021, reaching CNY 618 million (USD 92.7 million), with a CAGR of 72.4% from 2017 to 2021. Nicorandil dosage forms sold in China include tablets and injection, the latter already occupying the major share of the market in terms of sales value.
The analyst said that from 2022 to 2031, the number of patients with coronary heart disease and angina pectoris will continue to increase in China, and the demand for nicorandil in the Chinese market will continue to grow.
In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common risk of hypertension is coronary heart disease. By the end of 2021, the number of coronary heart disease patients in China is estimated to have exceeded 11 million, and this number is constantly rising due to environmental pollution and poor living habits.
Clinically, the WHO classifies coronary heart disease into five types: asymptomatic myocardial ischemia (occult coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart disease) and sudden death .
Angina is a clinical syndrome caused by acute and temporary ischemia and hypoxia of the myocardium due to insufficient blood supply to the coronary arteries. Population-based studies show that the incidence of angina increases with age, with prevalence rising from 5% to 7% in women aged 45 to 64 to 10% to 12% in women aged 65 to 84 years old, and from 4% to 7% among men aged 45-64 to 12%-14% among men aged 65-84.
The increasing number of coronary heart disease patients in China has contributed to the growth of the related drugs market.
Nicorandil is an antianginal drug that both relieves the symptoms of angina and improves the prognosis of coronary artery disease, with both nitrate-like and potassium-sensitive potassium channel-opening effects. the ATP. It can both dilate large coronary arteries and diastolic coronary microcirculatory resistance vessels, increasing coronary blood flow and myocardial oxygen supply while decreasing myocardial oxygen consumption, which effectively relieves angina from chest. Several global drug guidelines have made high-level recommendations for Nicorandil.
Nicorandil was developed by Chugai with SIGMART as the trade name. Nicorandil tablets were launched in Japan in 1984 as an anti-anginal drug while the injection was put into clinical use for unstable angina in 1993 and acute heart failure in 2007. The Chugai’s Nicorandil entered the Chinese market in 2009, and generic medicines from local China companies have been marketed ever since. In 2017, Nicorandil became reimbursable by Chinese medical insurance.
Topics Covered:
-
The impact of COVID-19 on the Chinese Nicorandil market
-
Development Environment of Nicorandil in China
-
Sales volume and value of Nicorandil in China
-
China Nicorandil Sales Volume and Value by Region
-
Top Nicorandil Manufacturers in China and Their Market Share
-
Nicorandil selling price in China
-
China Nicorandil Market Outlook, 2022-2031
Main topics covered:
1 Relevant concepts of nicorandil
1.1 Indications for nicorandil
1.2 Chinese Nicorandil Market Development
1.3 Government approval of Nicorandil in China
1.4 The impact of COVID-19 on the Chinese nicorandil market
2 China Nicorandil Sales, 2017-2021
2.1 Value of sales
2.1.1 China Sales Value
2.1.2 China Sales Value by Region
2.2 Sales volume
2.2.1 China Sales Volume
2.2.2 China Sales Volume by Region
2.3 China Nicorandil Sales by Dosage Form, 2017- 2021
2.3.1 Injection
2.3.2 Shelves
3 Analysis of Key Manufacturers of Nicorandil in China, 2017-2021
3.1 Market Share Analysis
3.1.1 Manufacturers Market Share by Sales Value
3.1.2 Manufacturers Market Share by Sales Volume
3.2 Beijing Sihuan Kebao Pharmaceutical Co., Ltd.
3.2.1 Company Profile
3.2.2 China Nicorandil Sales
3.3 Chugai Pharmaceutical Co., Ltd.
3.4 Xi’an Hanfeng Pharmaceutical Co., Ltd.
3.5 Henan Topfond Pharmaceutical Co., Ltd.
3.6 Shanxi Xin Yu Pharmaceutical Co., Ltd.
4 Nicorandil Sale Price by Different Companies in China, 2021-2022
4.1 Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi)
4.2 Chugai Pharmaceutical Co., Ltd. (SIGMART)
4.3 Xi’an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin)
4.4 Henan Topfond Pharmaceutical Co., Ltd. (TianFang)
4.5 Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang)
5 China Nicorandil Market Outlook, 2022- 2031
5.1 Factors Influencing Market Development
5.1.1 The impact of COVID-19 on the market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
For more information on this report visit https://www.researchandmarkets.com/r/6pq4gt
